Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial.

ABSTRACT:

Introduction

Post-ligation cardiac syndrome (PLCS) represents a state of severe post-intervention cardiopulmonary instability, seen in up to 50% of extremely premature infants after surgical closure of the patent ductus arteriosus (PDA); yet an evidence-based approach to treatment of this condition does not exist. The objective of this study is to determine the efficacy and safety of prophylactic milrinone in reducing incidence of PLCS and/or mortality within the first 7 days following PDA closure. The central hypothesis is that administration of intravenous milrinone will reduce the incidence of PLCS or death within 7 days of PDA closure either by percutaneous device (PCD) closure or surgical ligation (SL).

Methods and analysis

MIDAS (MIlrinone for prevention of post-patent

SUBMITTER: McNamara PJ 

PROVIDER: S-EPMC12382509 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature